These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26018735)

  • 1. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
    Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
    Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
    Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
    Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.
    Giunco S; Petrara MR; Zangrossi M; Celeghin A; De Rossi A
    Infect Agent Cancer; 2018; 13():14. PubMed ID: 29643934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
    Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
    J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
    Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
    J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
    Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
    Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBNA2 and activated Notch induce expression of BATF.
    Johansen LM; Deppmann CD; Erickson KD; Coffin WF; Thornton TM; Humphrey SE; Martin JM; Taparowsky EJ
    J Virol; 2003 May; 77(10):6029-40. PubMed ID: 12719594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase.
    Liu X; Cohen JI
    J Virol; 2016 Jan; 90(2):1129-38. PubMed ID: 26559845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
    Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes.
    Katsumura KR; Maruo S; Takada K
    J Med Virol; 2012 Mar; 84(3):504-10. PubMed ID: 22246839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
    Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
    J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
    Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
    Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
    Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
    Kalla M; Hammerschmidt W
    Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
    Ye J; Gradoville L; Daigle D; Miller G
    J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.
    Kim H; Choi H; Lee SK
    J Virol; 2016 Feb; 90(3):1359-68. PubMed ID: 26581978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.